arrow
L

Louise Kostos

Peter MacCallum Cancer Centre
H指数:12
被引数:578

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617

基线和早期治疗时外周血循环肿瘤DNA比例是接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌的关键预后生物标志物

2025-10-290
OAAI
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer

游离总前列腺特异性抗原比值作为转移性去势抵抗性前列腺癌生存的生物标志物

2025-04-250
OAAI
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

LuCAB临床试验方案:一项评估卡巴他赛联合[177Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的I-II期临床试验

2025-02-200
PRE
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

[177Lu]Lu-PSMA治疗后转移性去势抵抗性前列腺癌患者中的治疗相关髓系肿瘤:一个病例系列

2025-02-201
PRE
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T 161 Tb]Tb-PSMA-I&T

VIOLET的临床试验方案: [161 Tb] tb-psma-i & T转移性去势抵抗性前列腺癌患者放射配体治疗的单中心I/II期试验评估

2024-07-111
PRE
AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

字母: 镭-223和 [177Lu] lu-psma-i & T在患有转移性去势抵抗性前列腺癌的男性中的组合 (临床试验方案)

2022-11-1828
OAAI